NCT00689169已完成2 期
Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transplantation (ASCT)
Lymphoma Study Association1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Event free survival (EFS): events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined with high-dose BEAM followed by ASCT after first line treatment in patients aged from 18 to 65 years with poor prognosis CD 20 Diffuse Large B-Cell lymphoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged from 18 to 65 years.
- •Patient with pathologically proven, high grade B-cell Lymphoma CD 20 positive (WHO classification) :
- •Diffuse large B cell lymphoma.
- •Adverse prognostic factors IPI>1
- •In Complete Remission, or partial response to first line treatment.
- •Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP
- •Chemo-sensitive disease
- •PET Scan prior transplant
- •Eligible for autologous stem cell transplantation
- •With a minimum life expectancy of 3 months.
- •Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).
- •Having previously signed a written informed consent.
排除标准
- •Histological transformation in diffuse large B cell lymphoma, any type of low grade lymphoma
- •More than one line of treatment. Prior transplantation. Prior exposure to Zevalin
- •Central nervous system or meningeal involvement by lymphoma.
- •Contraindication to any drug contained in the chemotherapy regimen.
- •Any serious active disease or co-morbid medical condition (according to the investigator's decision and information provided in the IDB).
- •Poor renal function (creatinin level up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
- •Poor hepatic function (total bilirubin level up to 30 micro mol/l, transaminases up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
- •Poor bone marrow reserve as defined by neutrophils less than 1.5 G/l or platelets less than 100 G/l
- •Large bone marrow irradiation more than 40percent.
- •Bone marrow infiltration
- •Lack of sufficient autologous hematopoietic stem cells for transplantation.
- •Prior treatment with murine antibodies
- •Known hypersensibility to murine antibodies or proteins
- •Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
- •Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
- •Adult patient unable to give informed consent because of intellectual impairment.
- •Pregnant or lactating women.
研究组 & 干预措施
Experimental
Experimental
ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
干预措施: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) (Drug)
Experimental
Experimental
ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
干预措施: ASCT (Procedure)
Experimental
Experimental
ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
干预措施: Rituximab (Drug)
结局指标
主要结局
Event free survival (EFS): events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy
时间窗: 2 years
次要结局
- Overall response rate (ORR) (Complete Response CR and Partial Response PR)(100 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell LymphomaB-Cell LymphomaNCT00138086Lymphoma Study Association75
已完成
不适用
VMAT for Dominant Intraprostatic LesionProstate CancerNCT03030625Fundación de Investigación Biomédica - Hospital Universitario de La Princesa30
已完成
2 期
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodMyeloma, Plasma-CellLymphoma, MalignantMyeloproliferative DisordersMyelodysplastic SyndromesWaldenstrom's MacroglobulinemiaNCT00146055University of Michigan Rogel Cancer Center60
已完成
不适用
Pre-Surgical Intervention for Targeted Therapies for Breast CancerInvasive Breast CancerNCT01004744Columbia University10
Unknown
不适用
The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular DiseasesCardiovascular DiseasesDiabetes Mellitus, Type 2NCT00300976Japan Foundation for the Promotion of International Medical Research Cooperation2,542